The novel beta2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells
Journal article published in 2015 by
J. Kraus,
M. Kraus,
N. Liu,
L. Besse,
J. Bader,
P. P. Geurink,
Bruin G. De,
A. F. Kisselev,
H. Overkleeft 
,
C. Driessen
,
C. Driessen
